ValuEngine cut shares of Stemline Therapeutics (NASDAQ:STML) from a strong-buy rating to a buy rating in a research note published on Friday.
Other equities research analysts also recently issued research reports about the stock. HC Wainwright set a $38.00 price target on shares of Stemline Therapeutics and gave the stock a buy rating in a research note on Wednesday, June 6th. Cowen reiterated a buy rating on shares of Stemline Therapeutics in a research note on Thursday, May 10th. Zacks Investment Research downgraded shares of Stemline Therapeutics from a hold rating to a sell rating in a research note on Thursday, February 15th. Wedbush lifted their price target on shares of Stemline Therapeutics from $20.00 to $22.00 and gave the stock an outperform rating in a research note on Tuesday, May 29th. Finally, Roth Capital began coverage on shares of Stemline Therapeutics in a research note on Tuesday, June 12th. They set a buy rating and a $30.00 price target on the stock. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of Buy and an average price target of $30.00.
STML opened at $17.75 on Friday. Stemline Therapeutics has a fifty-two week low of $7.30 and a fifty-two week high of $20.55. The firm has a market cap of $538.88 million and a price-to-earnings ratio of -6.04.
Institutional investors and hedge funds have recently bought and sold shares of the business. Consonance Capital Management LP lifted its holdings in shares of Stemline Therapeutics by 2,216.9% during the fourth quarter. Consonance Capital Management LP now owns 2,349,792 shares of the biopharmaceutical company’s stock valued at $36,657,000 after acquiring an additional 2,248,372 shares during the period. Citadel Advisors LLC bought a new position in shares of Stemline Therapeutics during the first quarter valued at $8,948,000. venBio Select Advisor LLC bought a new position in shares of Stemline Therapeutics during the first quarter valued at $8,022,000. Nexthera Capital LP bought a new position in shares of Stemline Therapeutics during the first quarter valued at $8,011,000. Finally, Lyon Street Capital LLC lifted its holdings in shares of Stemline Therapeutics by 49.7% during the first quarter. Lyon Street Capital LLC now owns 1,241,293 shares of the biopharmaceutical company’s stock valued at $18,992,000 after acquiring an additional 412,203 shares during the period. Hedge funds and other institutional investors own 66.91% of the company’s stock.
About Stemline Therapeutics
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.